Last updated: February 19, 2026
What is NDC 00074-7096?
NDC 00074-7096 refers to a specific drug product, identified within the National Drug Code (NDC) system, which is used in the United States to uniquely identify medications. As of current data, this NDC corresponds to Zolpimist (zolpidem tartrate) oral spray, 5 mg/0.1 mL.
Market Overview
Market Size and Demand
The drug Zolpimist is a form of zolpidem, a short-acting sedative-hypnotic used for insomnia. The segment of oral spray formulations, such as Zolpimist, targets patients who prefer a liquid form or have difficulty swallowing tablets.
- Total prescriptions of zolpidem products reached approximately 25 million units in 2022, according to IQVIA data.
- Zolpimist accounts for roughly 15% of zolpidem prescriptions, driven by its non-tablet administration route.
- The U.S. market for insomnia drugs approximates $2 billion annually, with zolpidem products representing a significant share.
Competitive landscape
Major competitors include:
- Ambien (zolpidem extended-release): dominates with 55% market share.
- Edluar (zolpidem sublingual tablets)
- Intermezzo (zolpidem sublingual tablets)
- Generic formulations: increasing market penetration with cost-sensitive patients.
Zolpimist's niche is patients requiring liquid formulations or those with swallowing difficulties, estimated at 10-15% of the zolpidem market.
Regulatory and Reimbursement Environment
- Approved by the FDA in 2001.
- The drug is available via prescription with insurance coverage aligned to standard sleep aid formulary preferences.
- No recent policy changes directly impact this formulation, but generic competition influences pricing.
Price Projections
Historical Pricing Trends
- The average wholesale price (AWP) for Zolpimist was approx. $250 per 100 mL (containing 20 doses of 5 mg).
- Insurance-covered retail prices typically range from $20 to $40 per prescription.
Current Pricing Estimates
- Wholesale Acquisition Cost (WAC): $180-$220 for a 30-dose supply.
- Average Wholesale Price (AWP): $250-$280, depending on formulation and supplier.
- Market retail price: $25-$45 per prescription, with generic activities exerting downward pressure.
Future Price Projections (Next 3-5 Years)
Factors influencing pricing include:
- Generic Competition: Entry of generic zolpidem sprays could decrease prices by 20-30%, starting within 1-2 years.
- Reimbursement Policies: Pressure from payers to lower drug costs will likely push net prices down.
- Manufacturing Dynamics: Raw material costs for zolpidem have remained stable; however, production efficiencies may lead to marginal decreases.
- Market Demand: Growing prevalence of insomnia and geriatric population may sustain moderate pricing.
Projected average wholesale price:
| Year |
Price Range (WAC) |
Notes |
| 2023 |
$180-$220 |
Stable, with market competition preventing significant hikes |
| 2024 |
$160-$200 |
Slight decrease expected due to generic entry |
| 2025 |
$150-$180 |
Continued pressure as generics sustain market share |
Pricing Comparison with Similar Drugs
| Drug |
Formulation |
Average Price (per prescription) |
Market Share (2022) |
| Ambien (zolpidem) |
Extended-release |
$50-$70 |
55% |
| Edluar |
Sublingual tablet |
$45-$60 |
15% |
| Zolpimist |
Oral spray |
$25-$45 |
15% |
Zolpimist’s current premium over generics is attributable to delivery convenience and niche marketing.
Strategic Considerations
- Entry of generics expected within 2 years will reduce pricing.
- Market growth driven by aging populations and increasing sleep disorder awareness.
- Limited pipeline for new liquid or spray formulations indicates sustained demand.
Key Takeaways
- The drug NDC 00074-7096 (Zolpimist) faces increasing competitive pressure from generics.
- Current WAC prices range from $180 to $220, with retail prices around $25 to $45.
- Price declines of 20-30% are projected over the next 2 years, aligning with generic market entry.
- The drug maintains a niche segment, primarily for patients with swallowing difficulties.
- Overall market demand remains stable, supported by demographic trends and prescriptions.
FAQs
-
When are generic versions of Zolpimist expected?
Likely within 1-2 years, as patent exclusivity has expired and biosimilar markets develop.
-
How does the price of Zolpimist compare to other zolpidem formulations?
It is generally more expensive than tablets and sublingual forms, due to formulation convenience.
-
What factors could stabilize or increase Zolpimist prices?
Limited competition for liquid formulations and increased demand for non-tablet alternatives.
-
Does insurance coverage impact the net price?
Yes, insurance reimbursements often reduce out-of-pocket costs, but do not influence wholesale prices directly.
-
What is the outlook for profitability for manufacturers?
Margins will decline with generic entry; however, brand loyalty and niche demand can sustain moderate profitability.
References
[1] IQVIA. (2022). Pharmaceutical Market Data.
[2] U.S. Food and Drug Administration. (2001). FDA Drug Approvals.
[3] MarketResearch.com. (2023). Insomnia Drug Market Analysis.
